TAINAN, Taiwan, Nov. 25 /PRNewswire-Asia/ -- ScinoPharm, an active pharmaceutical ingredient (API) specialist, announced it has been granted US Patent No. 7,435,818 entitled "Novel Crystal Forms of Irinotecan Hydrochloride." The new patent provides for novel crystalline forms of irinotecan hydrochloride and processes for their preparation as well as pharmaceutical compositions containing the new forms and methods of treating metastatic carcinoma of the colon or rectum using these new forms.
This patent is the ninth US patent granted to ScinoPharm and the second patent for one of the company's high demand oncology products, irinotecan hydrochloride. ScinoPharm has already been granted a US Patent No. 7,157,179 covering the proprietary process for the preparation of a key intermediate of irinotecan hydrochloride.
The present invention provides crystalline forms of irinotecan hydrochloride that are more easily filtered from solution as compared to the existing forms of irinotecan hydrochloride. This increased ease of filtering promotes more efficient handling and processing of irinotecan hydrochloride during the manufacturing process, thus facilitating the formulation of new and improved pharmaceutical compositions which contain irinotecan hydrochloride.
"That we were awarded a US patent while other patent applications for the same polymorph are still pending in many other countries demonstrates our competence in the development and manufacture of oncological drug substances," stated Dr. Hardy Chan, CSO and Executive Vice President of ScinoPharm.
"And yet again we solidify our position as the world's leading supplier of irinotecan hydrochloride to the generic industry with adequate patent protection and continuous commitment to innovation," Dr. Chan added.
The latest patent adds to ScinoPharm's growing patent portfolio which now
consists of 11 granted patents and more than
|SOURCE ScinoPharm Taiwan, Ltd.|
Copyright©2008 PR Newswire.
All rights reserved